BioMark Diagnostics, Inc. · CSE:BUX

BioMark Diagnostics — Investor Presentation (July 2022)

33 slides from BioMark Diagnostics's investor presentation, July 2022

  1. Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence

    Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence

    A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND ARTIFICIAL INTELLIGENCE

  2. Slide 2: Our Mission / Who We Are

    Slide 2: Our Mission / Who We Are

    Our Mission Who We Are • Developer of a metabolomics liquid biopsy- Provide better cancer detection, based platform leveraging machine learning monitoring and screening solutions for with advanced near-to-market diagnostic hard to detect cancers technologies. • Multiple IP’s in detection and quantit

  3. Slide 3: Metabolomics

    Slide 3: Metabolomics

    METABOLOMICS me·​tab·​o·​lo·​mics | \ mə-ˈta-bə-ˌlō-miks : a form of clinical chemistry that uses advanced analytical techniques to measure the complete collection of “small molecules” found in a given biological sample that offers rapid, inexpensive, comprehensive, quantitative characterization of…

  4. Slide 4: The Advantages of Metabolomics

    Slide 4: The Advantages of Metabolomics

    THE ADVANTAGES OF METABOLOMICS There are differences in the genomes of cancer cells and tissues in different cancer patients. This heterogeneity of cancer cells impacts the accuracy and applicability of many diagnostic markers for genes and proteins. These markers for genes and proteins may be effec

  5. Slide 5: Cancer Is a Metabolic Disease

    Slide 5: Cancer Is a Metabolic Disease

    CANCER IS A METABOLIC DISEASE 5 Source: Hallmarks of Cancer - Hanahan D, Wienberg RA (2011) Cell, 144:646-674.

  6. Slide 6: Early Detection Is Critical to Save Lives

    Slide 6: Early Detection Is Critical to Save Lives

    EARLY DETECTION IS CRITICAL TO SAVE LIVES 6

  7. Slide 7: Global Cancer Biomarkers Market

    Slide 7: Global Cancer Biomarkers Market

    GLOBAL CANCER BIOMARKERS MARKET Forecast to 2028 Growth Drivers : Market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer. Rising technolo

  8. Slide 8: Liquid Biopsy Platform & Product Pipeline

    Slide 8: Liquid Biopsy Platform & Product Pipeline

    LIQUID BIOPSY PLATFORM & PRODUCT PIPELINE Completed development of 2 metabolomic assays – Platform Play Planning Development Validation Regulatory Approval Market Customize assay; Collect more clinical data and Lung Cancer Metabolic Fingerprint Assay build LDT for early lung cancer detection and scr

  9. Slide 9: Projects in Process

    Slide 9: Projects in Process

    PROJECTS IN PROCESS Metabolomic Fingerprint Assay Development Early Lung cancer - 1200 retrospective studies following 260 trial at IUCPQ for early detection of lung cancer. Expanded the sample size to include more subtypes, other lung diseases, other morbidities and different cancers. – Sponsored r

  10. Slide 10: Patent Family in Use in Different Jurisdictions

    Slide 10: Patent Family in Use in Different Jurisdictions

    PATENT FAMILY IN USE IN DIFFERENT JURISDICTIONS SSAT1 use for Early lung cancer GBM therapeutic response to treatment detection target in lung and brain METHOD OF DETECTING LUNG cancers CANCER GLIOBLASTOMA TUMOR GROWTH INHIBITON BY SAT1 METHOD OF DETECTING KNOCKDOWN A METHOD FOR ASSAYING THE CANCER

  11. Slide 11: Lung Cancer Metabolic Fingerprint Assay

    Slide 11: Lung Cancer Metabolic Fingerprint Assay

    Lung Cancer Metabolic Fingerprint Assay 11

  12. Slide 12: Lung Cancer – The Big Picture

    Slide 12: Lung Cancer – The Big Picture

    LUNG CANCER – THE BIG PICTURE Lung cancer has been the most Most common common cancer in the world for several decades and accounts for 1 in 5 of all cancer deaths. Worldwide, three people die from lung Deadly cancer every minute Because of the lower specificity of LDCT, 96 % of all nodules discover

  13. Slide 13: Lung Cancer – Stage Shifting Impact

    Slide 13: Lung Cancer – Stage Shifting Impact

    LUNG CANCER – STAGE SHIFTING IMPACT • The lung cancer five-year survival rate (18.6 percent) is lower than many other leading cancer sites, such as colorectal (64.5 percent), breast (89.6 percent) and prostate (98.2 percent). • The five-year survival rate for lung cancer is 56 percent for cases dete

  14. Slide 14: Lung Cancer Screening Highlights

    Slide 14: Lung Cancer Screening Highlights

    LUNG CANCER SCREENING HIGHLIGHTS Large Undeserved Market Target - Lung Cancer Screening for identified high risk groups to complement LDCT Scan Estimated Population Size : 16 million in USA 1.4 million in Canada 0.4 million in Québec only Current Uptake 5% in USA – No organized lung cancer screening

  15. Slide 15: Strong Tailwinds

    Slide 15: Strong Tailwinds

    STRONG TAILWINDS Active VA screening programs seeking better Current lung cancer Limited access to LDCT screening technology for at screening rates in US is especially in rural risk veterans across the estimated at 5% communities country. Program being funded under NCI Cancer Moonshot has been reign

  16. Slide 16: Established Accepted Test (LDT) Coupled with Robust Technology Backbone

    Slide 16: Established Accepted Test (LDT) Coupled with Robust Technology Backbone

    ESTABLISHED ACCEPTED TEST (LDT) COUPLED WITH ROBUST TECHNOLOGY BACKBONE The lung cancer metabolites are easily measured using quantitative mass spectrometry (MS) methods with standard instruments used in diagnostic clinical laboratories across Canada and USA. • the amount of blood required (<20 µL),

  17. Slide 17: Targeted Metabolomics Lung Cancer Trials

    Slide 17: Targeted Metabolomics Lung Cancer Trials

    Targeted Metabolomics Lung Cancer Trials Data Summary Total Subjects: 257 Normal: 60 Lung Cancer: 197 (emphasis on Stages 1 and 2) Metabolomics Analysis: Human plasma samples* were analyzed using custom developed assay for several putative lung cancer biomarkers. *Samples and data obtained from IUCP

  18. Slide 18: Strong Performance for Early-Stage Detection

    Slide 18: Strong Performance for Early-Stage Detection

    STRONG PERFORMANCE FOR EARLY-STAGE DETECTION Logistic regression based optimal model for stages I + II Logistic regression based on optimal model for stages I + II NSCLC detection: metabolites only NSCLC detection: metabolites plus smoking history 18

  19. Slide 19: Strong Performance for Early-Stage Detection

    Slide 19: Strong Performance for Early-Stage Detection

    STRONG PERFORMANCE FOR EARLY-STAGE DETECTION P E R F O R M AN C E O F L O G I S T I C R E G R E S S I O N P E R F O R M AN C E O F L O G I S T I C R E G R E S S I O N MODEL A MODEL B AUC SENSITIVITY SPECIFICITY AUC SENSITIVITY SPECIFICITY TRAINING/ 0.974 (0.965 ~ 0.937 (0.920 ~ 0.922 (0.895 ~ TRAINI

  20. Slide 20: BioMark's Advantage Over LDCT Scan for Lung Cancer Screening

    Slide 20: BioMark's Advantage Over LDCT Scan for Lung Cancer Screening

    BIOMARK’S ADVANTAGE OVER LDCT SCAN FOR LUNG CANCER SCREENING LDCT BIOMARK’S LIQUID BIOPSY 73.4% (SPECIFICITY) 96.1% (SPECIFICITY) % EARLY STAGE DETECTION 93.8% (SENSITIVITY) 94.4% (SENSITIVITY) FALSE POSITIVE RATES HIGH MUCH LOWER COST >$1000 <$400 RADIATION IMPACT OVER 18% COMPLICATIONS NONE False

  21. Slide 21: Impending Catalyst – Short Term Canada

    Slide 21: Impending Catalyst – Short Term Canada

    IMPENDING CATALYST – SHORT TERM CANADA Lung Cancer Panel Assay Development Timeline Stage I/II Lung Cancer Present Discovery Screening data to Study Open R&D Internal Validation CQDM regulatory Publication Facilities in Qc Assay V&V (4000 samples) agencies 2020 2021 2022 2023 Partnership with Clinic

  22. Slide 22: Lung Cancer Screening Validation Outline - Ongoing

    Slide 22: Lung Cancer Screening Validation Outline - Ongoing

    LUNG CANCER SCREENING VALIDATION OUTLINE - ONGOING DISCOVERY COHORT VALIDATION COHORT Screening project T1 year T2 year T3 year Patient selection (PanCan risk model); n=3000 Genetic Clinical follow-up profile No lesion IUCPQ Biobank Polygenic score Low risk lesion EGFR Status 4,000 lung lesion patie

  23. Slide 23: Options for Growth

    Slide 23: Options for Growth

    OPTIONS FOR GROWTH Lung Cancer - Panel Assay • ISO -15189 accredited lab services • Establish beachhead in Quebec with IUCPQ and expand services across Canada • Discuss collaboration with VHA (Veterans Health Authority) • Build / Acquire Labs or Partner in US for assay validation with licensing opti

  24. Slide 24: Catalysts in Q2 and Q3 2022

    Slide 24: Catalysts in Q2 and Q3 2022

    CATALYSTS IN Q2 AND Q3 2022 Complete 1200 retrospective lung cancer analysis and data readout – Medteq and Sparks Grant funded study Conduct V&V studies for lab accreditation based on 1200 lung cancer samples Present at ASMS in June 2022 to demonstrate the clinical validation and utility of BioMark’

  25. Slide 25: Value Proposition – Actionable Diagnostic Test

    Slide 25: Value Proposition – Actionable Diagnostic Test

    VALUE PROPOSITION- ACTIONABLE DIAGNOSTIC TEST Our technology solution – offers • Early diagnosis and screening – Application in screening for aggressive and hard to detect cancers such as lung and brain cancers. • Effective monitoring tool to assess treatment efficacy earlier so as to improve tailor

  26. Slide 26: Management Team – Rashid A. Bux

    Slide 26: Management Team – Rashid A. Bux

    MANAGEMENT TEAM Rashid A.Bux - Founder & CEO Rashid Ahmed - Founder and CEO of BioMark Diagnostics Inc, started his journey into the medical sector as a science student at Nairobi University. He holds a Master of Business Administration from the University of Western Ontario and a Bachelor of Scienc

  27. Slide 27: Management Team – Dr. Jean-Francois Haince

    Slide 27: Management Team – Dr. Jean-Francois Haince

    MANAGEMENT TEAM Dr. Jean-Francois Haince - CSO and GM Dr. Haince holds a PhD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. He cumulates over 15 years of experience in cancer research and authored over 20 peer-reviewed scientific publications. During his term at

  28. Slide 28: Management Team – Guoyu Huang

    Slide 28: Management Team – Guoyu Huang

    MANAGEMENT TEAM Guoyu Huang – CFO Guoyu (Gina) Huang, the CFO of BioMark Diagnostics Inc. and the President of BioMark Diagnostic Solutions Inc, has been a core management team member of BioMark since 2013. With the ability and experience to examine and understand business needs and deliver comprehe

  29. Slide 29: BioMark Corporate Structure

    Slide 29: BioMark Corporate Structure

    BIOMARK CORPORATE STRUCTURE 29

  30. Slide 30: Current Facilities in North America & Global Network

    Slide 30: Current Facilities in North America & Global Network

    CURRENT FACILITIES IN NORTH AMERICA & GOBAL NETWORK Clinical Laboratory Québec, Canada University of Brescia Astrazeneca Global China Italy UK Bangladesh Head Office Vancouver, Canada Pfizer Canada France Mount Sinaï New York, USA Brazil 30

  31. Slide 31: BioMark Cap Table Summary

    Slide 31: BioMark Cap Table Summary

    BIOMARK CAP TABLE SUMMARY • Trading Symbols: CSE: BUX / OTCMKTS: BMKDF / FSE: 20B • Common Shares Issued and Outstanding: 83,286,229 • Warrants (@ $0.45): 6,177,579 • Options (@ $0.15 - $0.30): 4,135,000 • Insiders ownership: 65% • Capital Raised (to-date): CAD $ 14.5 m 31

  32. Slide 32: What We Offer

    Slide 32: What We Offer

    WHAT WE OFFER • Disciplined scale • Growth oriented • Solid Platform for hard to detect and treat cancers -Near commercial ready assays • Strong sponsored research – peer reviewed/validation • IP portfolio • Defined route to revenue. Strategy and approach is defensible • Clinical partners • Executio

  33. Slide 33: Contact Details

    Slide 33: Contact Details

    Contact Details Rashid Bux Founder and CEO rahmed@biomarkdiagnostics.com Mobile: 1- 604-836-6950 www.biomarkdiagnostics.com A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND 33 ARTIFICIAL INTELLIGENCE

Source: Internet Archive copy of biomarkdiagnostics.com

More decks from BioMark Diagnostics, Inc.

All 7 BioMark Diagnostics decks